Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06938867 · ClinicalTrials.gov registry record · Phase 1
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
A Phase 1 study of E Coli Infections and Allogenic Transplant Patients, sponsored by SNIPR Biome Aps..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 8
- Study locations
NCT06938867 is a Phase 1 study of E Coli Infections and Allogenic Transplant Patients that is actively recruiting participants, run by SNIPR Biome Aps.. The registered enrollment target is 24 participants. The trial reports 8 study locations across 7 states.
The verdict
NCT06938867, a Phase 1 study of E Coli Infections and Allogenic Transplant Patients, is actively recruiting participants, sponsored by SNIPR Biome Aps..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 1b/2a study in allogenic hematopoietic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC levofloxacin.
Conditions Studied
Interventions
- BIOLOGICAL SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli
- OTHER Placebo 10 mL
Study Locations (8)
California
- City of Hope - Duarte
- University of California, San Francisco - San Francisco
Maryland
- John Hopkins University - Baltimore
Minnesota
- University of Minnesota - Minneapolis
New York
- Weill Cornell Medicine - New York
Pennsylvania
- UPMC - Pittsburgh
Texas
- University of Texas MD Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06938867
The ClinicalTrials.gov registry entry for NCT06938867 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SNIPR Biome Aps., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with E Coli Infections appearing as the primary indexed condition, and to 2 interventions - of which SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli is the first listed.
NCT06938867 reports 8 study locations spanning 7 distinct geographic areas - top geographies include California, Maryland, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06938867 about?
NCT06938867 is a clinical study titled "Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant". This is a Phase 1b/2a study in allogenic hematopoietic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC levofloxacin.
What is the current status of trial NCT06938867?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-02-25. Estimated completion is 2026-04-01.
What conditions does trial NCT06938867 study?
This clinical trial studies the following conditions: E Coli Infections, Allogenic Transplant Patients.
What interventions are being tested in trial NCT06938867?
The interventions under investigation include: SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli (BIOLOGICAL), Placebo 10 mL (OTHER).
Who is sponsoring clinical trial NCT06938867?
This trial is sponsored by SNIPR Biome Aps., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06938867 being conducted?
This trial has 8 study locations across California, Maryland, Minnesota, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for E Coli Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.